Benign Breast Disease and Early Breast Cancer Market: Epidemiology, Therapies, Companies, DelveInsight | Abbott Laboratories Inc., AbbVie Inc., Amgen Inc,, Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd, Bristol, Myers Squibb Company, Eisai Inc.

Benign Breast Disease and Early Breast Cancer therapies, such as ECHOPULSE, ProSense, and others, are expected to boost the Benign Breast Disease and Early Breast Cancer Market in the upcoming years.

DelveInsight has launched a new report on "Benign Breast Disease and Early Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Benign Breast Disease and Early Breast Cancer, historical and forecasted epidemiology as well as the Benign Breast Disease and Early Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Benign Breast Disease and Early Breast Cancer market report @ https://www.delveinsight.com/report-store/benign-breast-disease-and-early-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Benign Breast Disease and Early Breast Cancer Market Report:

The **Benign Breast Disease and Early Breast Cancer Market** in the **7MM (US, EU4, UK, and Japan)** is projected to grow at a significant compound annual growth rate (CAGR) throughout the 2020-2034 study period.
In September 2024, the U.S. Food and Drug Administration (FDA) approved Novartis' Kisqali® (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive, HER2-negative (HR+/HER2-) stage II and III early breast cancer at high risk of recurrence. This approval is based on the Phase III NATALEE trial, which demonstrated that Kisqali significantly reduced the risk of recurrence by 25% compared to endocrine therapy alone. Notably, the benefit was consistent across all subgroups, including patients with node-negative disease .
In the United States alone, **biopsy-confirmed benign breast disease** is diagnosed about **four times more often** than invasive breast cancer, impacting **around 1 million women annually**. This indicates a strong market opportunity, as early-stage and benign breast conditions affect a broader population than advanced breast cancer.
In 2023, the **U.S. held the largest market share** for benign and early breast cancer within the 7MM. Within Europe, **Germany led among the EU4 and UK**, while **Spain recorded the smallest share**.
The **COVID-19 pandemic** had a substantial effect on breast cancer care-screening programs were paused, some systemic treatments were delayed, and surgeries, including reconstructive and preventive procedures, were postponed.
Compared to breast cancer, there is a **notable lack of clinical guidelines and research** surrounding the investigation and management of benign breast disease. For instance, no standard imaging surveillance protocols exist for patients post-mastectomy.
In 2023, the United States accounted for the highest number of new cases of benign breast disease and early breast cancer among the 7MM, representing approximately 49% of the total. That year, the U.S. reported around 1.4 million cases of benign breast disease and approximately 243,500 cases of early-stage breast cancer. The EU4 and the UK followed, with Japan contributing the smallest share.
Among all benign breast conditions, **fibroadenoma** is the most frequently diagnosed subtype in the U.S., representing **about 70% of all benign breast disease cases**.
Key Benign Breast Disease and Early Breast Cancer companies such as Abbott Laboratories Inc., AbbVie Inc., Amgen Inc,, Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd, Bristol, Myers Squibb Company, Eisai Inc., and others are evaluating new drugs for Benign Breast Disease and Early Breast Cancer to improve the treatment landscape.
Promising Benign Breast Disease and Early Breast Cancer therapies include ECHOPULSE, ProSense, and others.

Benign Breast Disease and Early Breast Cancer Overview

Benign breast disease encompasses a range of non-cancerous breast lesions that are commonly detected through clinical exams, imaging, self-examination, or due to symptoms like breast pain (mastalgia). Once imaging and, if necessary, biopsy confirm a benign diagnosis, treatment typically focuses on relieving symptoms and educating the patient-without the need for surgery. These conditions are more frequently seen in younger women, with incidence starting to rise in the teenage years and peaking between ages 40 and 50.

Early breast cancer refers to cancer that remains confined to the breast and possibly the nearby underarm lymph nodes, without spreading to other parts of the body. It typically includes **Stage 0, Stage I, and Stage II** breast cancers, as defined by the number staging system.

Benign Breast Disease and Early Breast Cancer Market Outlook

The current market is categorized based on widely adopted treatment approaches across the 7MM, with slight differences in therapeutic practices. Surgical interventions-such as lumpectomy, mastectomy, minimally invasive procedures, and excisional surgery for benign breast disease-are the primary treatment options reflected in the forecast model.

In 2023, the total market size for Benign Breast Disease and Early Breast Cancer in the 7MM was estimated at approximately USD 8.8 billion and is expected to grow over the 2024-2034 forecast period. The United States held the largest market share, accounting for about 51%, followed by the EU4 and the UK, which together made up around 42% of the market.

Discover how the Benign Breast Disease and Early Breast Cancer market is rising in the coming years @ https://www.delveinsight.com/sample-request/benign-breast-disease-and-early-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Benign Breast Disease and Early Breast Cancer Marketed Drugs
ECHOPULSE: Theraclion
ProSense: IceCure Medical
Scope of the Benign Breast Disease and Early Breast Cancer Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Benign Breast Disease and Early Breast Cancer Companies: Abbott Laboratories Inc., AbbVie Inc., Amgen Inc,, Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd, Bristol, Myers Squibb Company, Eisai Inc., and others
Benign Breast Disease and Early Breast Cancer Therapeutic Assessment: Benign Breast Disease and Early Breast Cancer current marketed and Benign Breast Disease and Early Breast Cancer emerging therapies
Benign Breast Disease and Early Breast Cancer Market Dynamics: Benign Breast Disease and Early Breast Cancer market drivers and Benign Breast Disease and Early Breast Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Benign Breast Disease and Early Breast Cancer Unmet Needs, KOL's views, Analyst's views, Benign Breast Disease and Early Breast Cancer Market Access and Reimbursement

To know what's more in our Benign Breast Disease and Early Breast Cancer report, visit https://www.delveinsight.com/report-store/benign-breast-disease-and-early-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Benign Breast Disease and Early Breast Cancer Market Report:
Benign Breast Disease and Early Breast Cancer market report covers a descriptive overview and comprehensive insight of the Benign Breast Disease and Early Breast Cancer Epidemiology and Benign Breast Disease and Early Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Benign Breast Disease and Early Breast Cancer market report provides insights into the current and emerging therapies.
The Benign Breast Disease and Early Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Benign Breast Disease and Early Breast Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Benign Breast Disease and Early Breast Cancer market.

Got queries? Click here to know more about the Benign Breast Disease and Early Breast Cancer market Landscape https://www.delveinsight.com/sample-request/benign-breast-disease-and-early-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Benign Breast Disease and Early Breast Cancer Patient Share (%) Overview at a Glance
5. Benign Breast Disease and Early Breast Cancer Market Overview at a Glance
6. Benign Breast Disease and Early Breast Cancer Disease Background and Overview
7. Benign Breast Disease and Early Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Benign Breast Disease and Early Breast Cancer
9. Benign Breast Disease and Early Breast Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Benign Breast Disease and Early Breast Cancer Emerging Therapies
12. Benign Breast Disease and Early Breast Cancer Market Outlook
13. Country-Wise Benign Breast Disease and Early Breast Cancer Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Benign Breast Disease and Early Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Benign Breast Disease and Early Breast Cancer Market Outlook 2034 https://www.delveinsight.com/report-store/benign-breast-disease-and-early-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Benign Breast Disease and Early Breast Cancer Pipeline Insights, DelveInsight

"Benign Breast Disease and Early Breast Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Benign Breast Disease and Early Breast Cancer market. A detailed picture of the Benign Breast Disease and Early Breast Cancer pipeline landscape is provided, which includes the disease overview and Benign Breast Disease and Early Breast Cancer treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.